Jubilant Life Sciences and Gilead Sciences sign licensing deal for Remdesivir
Jubilant Life Sciences and Gilead Sciences sign licensing deal for Remdesivir India’s Jubilant Life Sciences and US-based Gilead Sciences signed a non-exclusive licensing agreement on Tuesday for manufacturing remdesivir, a drug which has been identified as a potential therapy for Covid-19. https://ift.tt/eA8V8J
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment